{"title":"Recent advances in nano-molybdenum oxide for photothermal cancer therapy.","authors":"Shihai Chen, Ping Zhang, Hongmei Bai, Wenhui Yi","doi":"10.1080/17435889.2025.2476386","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer remains a significant global health challenge, driving the search for innovative treatments. Photothermal therapy (PTT) has emerged as a promising approach, using photothermal agents to convert near-infrared (NIR) light into heat for tumor ablation. Among these agents, nano-molybdenum oxide, particularly non-stoichiometric MoO<sub>3-x</sub> (0 < x < 1), stands out due to its unique defect structure, strong NIR absorption, high photothermal conversion efficiency (PCE), and pH-responsive degradation. This review summarized recent advancements in nano-molybdenum oxide for PTT, covering its classification, synthesis, surface modification, and tumor-targeting mechanisms. Subsequently, we explored its applications in PTT and combination therapies, evaluated biocompatibility and toxicity, and discussed current achievements, challenges, and future perspectives in cancer treatment.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-19"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2476386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer remains a significant global health challenge, driving the search for innovative treatments. Photothermal therapy (PTT) has emerged as a promising approach, using photothermal agents to convert near-infrared (NIR) light into heat for tumor ablation. Among these agents, nano-molybdenum oxide, particularly non-stoichiometric MoO3-x (0 < x < 1), stands out due to its unique defect structure, strong NIR absorption, high photothermal conversion efficiency (PCE), and pH-responsive degradation. This review summarized recent advancements in nano-molybdenum oxide for PTT, covering its classification, synthesis, surface modification, and tumor-targeting mechanisms. Subsequently, we explored its applications in PTT and combination therapies, evaluated biocompatibility and toxicity, and discussed current achievements, challenges, and future perspectives in cancer treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
